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Flavonoids, a group of dietary polyphenols have been shown to possess cognitive health beneﬁts.
Epidemiologic evidence suggests that they could play a role in risk reduction in dementia. Amyloid
precursor protein processing and the subsequent generation of amyloid beta (Ab) are central to the
pathogenesis of Alzheimer’s disease, as soluble, oligomeric Ab is thought to be the toxic species driving
disease progression. We undertook an in vitro screen to identify ﬂavonoids with bioactivity at bg-
mediated amyloid precursor protein processing, which lead to identiﬁcation of a number of ﬂavonoids
bioactive at 100 nM. Because of known bioavailability, we investigated the catechin family further and
identiﬁed epigallocatechin and ()-epicatechin as potent (nanomolar) inhibitors of amyloidogenic pro-
cessing. Supporting this ﬁnding, we have shown reduced Ab pathology and Ab levels following short
term, a 21-day oral delivery of ()-epicatechin in 7-month-old TASTPM mice. Further, in vitro mecha-
nistic studies suggest this is likely because of indirect BACE1 inhibition. Taken together, our results
suggest that orally delivered ()-epicatechin may be a potential prophylactic for Alzheimer’s disease.
 2015 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
Since its conception in the early 1990s, the amyloid cascade
hypothesis has remained central to research into the development
of therapeutics for the treatment of Alzheimer’s disease (AD)
(Hardy and Higgins, 1992). It states that misregulation of amyloid
beta (Ab) production leads to Ab accumulation and deposition,
aberrant signaling, and downstream neurotoxicity (Hardy, 2009;e CC BY license (http://
and Biochemistry, University
0) 1225 386553; fax: þ44 (0)
s).
tive Medicines, MedImmune
Published by Elsevier Inc. All righHardy and Allsop, 1991; Hardy and Higgins, 1992). The lack of
successful drugs targeting Ab, however, has created a signiﬁcant
unmet need for alternative approaches to AD treatment.
Flavonoids are a group of several thousand polyphenolic com-
pounds distinguished by the presence of 2 phenyl rings connected
by benzene. They are subcategorized into 6 groups dependent on
structure: ﬂavanols, ﬂavanones, ﬂavonols, ﬂavones, isoﬂavones, and
anthocyanins. As secondary metabolites in fruits and vegetables,
ﬂavonoids are present in human diet (Commenges et al., 2000;
Letenneur et al., 2007). Once ingested, ﬂavonoids are extensively
metabolized; they can be glycosylated, methoxylated, sulfated,
esteriﬁed, or polymerized (Manach et al., 2004). There is great
variability in ﬂavonoid bioavailability; many are directly excreted
but some ﬂavonoids or their metabolites are detectable in the
bloodstream hours after ingestion (Ramassamy, 2006). Although
difﬁcult to analyze because of extensive metabolism, it has been
shown that concentrations of approximately 200e400 nM ofts reserved.
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Wang et al., 2012).
The actions of ﬂavonoids have classically been attributed to their
antioxidant properties (Rice-Evans et al., 1996). This has recently
been questioned because of low concentrations of ﬂavonoids
achievable in the brain, meaning they are unlikely to be beneﬁcial
over the endogenous antioxidants such as ascorbate (Williams
et al., 2004). Transgenic mouse models of AD have been used to
demonstrate that selected ﬂavonoids have beneﬁcial effects on
different aspects of the pathology. Tg2576 mice orally administered
the ﬂavanol epigallocatechin gallate (EGCG), showed reduced am-
yloid pathology, and improved cognitive function (Rezai-Zadeh
et al., 2008); this was shown in a separate study to be via activa-
tion of ADAM10, the a-secretase (Obregon et al., 2006). A ﬂavonoid-
rich grape seed polyphenolic extract orally delivered for 5 months
also showed reduced Ab pathology; however, this was shown to be
via inhibition of Ab aggregation (Wang et al., 2008). Monomeric
synthetic 30-O-methyl-epicatechin-5-O-glucuronide derived from
the grape seed polyphenolic extract, when given orally for
5 months, showed positive effects on synaptic transmission and
long-term potentiation, through the CREB signaling (Wang et al.,
2012). Although these studies show promising results for ﬂavo-
noids, they have typically been carried out on a chosen compound
or small subset of compounds, looking at their effects in isolation
and there have been inconsistencies in ﬁndings and lack of a
coherent, systematic approach to looking across the family as a
whole.
The challenge is to study the actions of ﬂavonoids so that the
most effective molecules for the modulation of amyloid precursor
protein (APP) processing can be identiﬁed. We systematically
assessed a range of isolated ﬂavonoid compounds from across the
different groups for inhibition of bg-secretase mediated APP pro-
cessing using an established bg reporter assay. From this initial
in vitro screen, the ﬂavanol subfamily were focused on for more
detailed concentration and kinetic analyses followed by in vivo
analysis of the most potent inhibitory compound, ()-epicatechin.
Oral ()-epicatechin reduced Ab pathology in TASTPM mice
providing further evidence for the development of monomeric
ﬂavonoid compounds as therapeutic agents for the treatment or
prevention of AD.
2. Methods
2.1. Compounds
Flavonoids were purchased from Extrasynthese and made up as
10 mM stocks in methanol. N-[n-(3,5-diﬂuorophenactetyl)-L-
alanyl]-(S)-phenylglycine t-butyl ester (DAPT) was purchased from
Tocris. TAPI-1 was purchased from Enzo Life Sciences. APP b-sec-
retase inhibitor (bsI) and b-secretase inhibitor IV (bIV) were pur-
chased from Calbiochem. TAPI, DAPT, bsI, and bIV were made up as
1000 concentrated stocks in DMSO (Sigma).
2.2. Plasmids
pRC-CMV-APP695-Gal4 and pRC-CMV-APP695-Gal4D were as
described previously (Hoey et al., 2009). pFR-Luciferase reporter
vector with ﬁreﬂy (Photinus pyralis) luciferase gene under the
control of a synthetic promoter containing 5 tandem repeats of the
yeast Gal4 upstream activation sequence upstream of a minimal
TATA box and phRL thymidine kinase (TK) vector containing sea
pansy (Renilla reniformis) luciferase gene under control of the her-
pes simplex viruseTK promoter, from Promega. pC1-CMV vector
containing complementary DNA (cDNA) encoding human Fe65 has
been described previously (Perkinton et al., 2004). pSecTag2 vectorcontaining cDNA encoding for human Notch3 fused in frame at its C
terminus to the yeast transcription factor GAL4was kindly provided
by Dr Michael Perkinton (King’s College, London).
2.3. pRC-APP695-Gal4 site-directed mutagenesis
pRC-CMV vector containing a cDNA encoding for the Swedish fa-
milial mutation of human APP695 fused in-frame at its C-terminus to
theGal4yeast transcription factorwascreatedusingpRC-APP695-Gal4
plasmid (kind gift of Prof. Tommaso Russo, University of Naples) and
introduction of a double point mutation at positions 595/596 of
APP695 using the QuikChange XL Site-Directed Mutagenesis kit
according to the manufacturer’s instructions (Stratagene). Mutagen-
esis primers used APPswe forward primer 50-GAGATCTCTGAAGT-
GAATCTGGATGCAGAATTCCGA-30 and APPswe reverse primer 50-
TCGGAATTCTGCATCCAGATTCACTTCAGAGATCTC-30.
2.4. Primary neuronal culture
Primary cortical neuronal cultures were prepared as described
previously (Hoey et al., 2009). Cortices were dissected from em-
bryonic day 15 CD1 or TASTPM embryos and mechanically disso-
ciated using a serum-coated ﬁre-polished Pasteur pipette in PBS þ
6 mM D-glucose (Ca2þ and Mg2þ free). Neurons were plated into
multiwell tissue culture plates (Nunc) that were precoated with
20 mg/mL poly-D-lysine (Sigma) and were maintained in Neuro-
basal medium minus phenol red, supplemented with B-27, 2 mM
glutamine, 100 mg/mL streptomycin, and 50 mg/mL penicillin
(Invitrogen), at 37

C in a humidiﬁed atmosphere of 95% air and 5%
CO2. Cultures were used after 5e10 DIV.
2.5. Dual-Glo luciferase gene reporter assay
pRC-APP695-Gal4, pFR-Luciferase, pRC-APP695-Gal4DBD, pSec-
Tag2-Notch3Gal4, and pC1-Fe65 plasmids (all 0.5 mg) were trans-
fected into primary cortical neurons cultured in 12-well plates
(0.5  106 cells per well) at 5 DIV, using Lipofectamine 2000 (1 mL/
well), as detailed in legend. All wells were cotransfected with phRL-
TK Renilla (0.5 mg) as in internal control for luciferase expression.
Transfection mixes containing lipid and DNA were prepared sepa-
rately in OptiMEM I reduced serum medium (Invitrogen), then
mixed and incubated at RT for 25 minutes. Neuronal cultures were
removed from the incubator and 150 mL/well transfection mix was
added dropwise to the culture medium. Cultures were then placed
back in the incubator. Transfected neurons were treated with
different compounds as detailed in legends and processed 24e30
hours posttransfection for quantiﬁcation of ﬁreﬂy luciferase and
Renilla luciferase expression. Neurons were lysed with Glo lysis
buffer (100 mL/well) (Promega), and the Dual-Glo luciferase activity
assay was performed according to the manufacturer’s instructions
(Promega). Luciferase signals were captured using a microplate
luminometer (BMG Labtech). Fireﬂy luciferase reporters activity
was normalized using the Renilla luciferase activity, which helps to
differentiate between speciﬁc and nonspeciﬁc cellular responses
and control for transfection efﬁciencies across experiments.
2.6. Recombinant BACE1 assay
The BACE1 activity detection assay was performed according to
the manufacturer’s instructions (Sigma, MO, USA). Assay compo-
nents were mixed to a ﬁnal volume of 100 mL in a black 96-well
microplate. Test samples were incubated with inhibitors or ﬂavo-
noid compounds as indicated in the ﬁgure legends. Fluorescence
readings (excitation 320 nm and emission 405 nm) were taken at
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Stop solution was then added.
To measure endogenous BACE1 activity levels in 6 DIV primary
cortical cultures (3.3  105 cells per well) were treated, as detailed
in ﬁgure legends, directly into the conditioned media. Following
treatment, the media were aspirated, and wells were washed once
with cold PBS. CelLytic M (200 mL; Sigma, MO, USA) was added to
each well. Wells were then scraped and cellular material trans-
ferred to fresh microcentrifuge tubes. These were then centrifuged
(2000 g for 5 minutes) and the supernatant transferred to a new
microcentrifuge tube. Cell lysates (30 mL) were then incubated with
synthetic BACE1 substrate, and ﬂuorescent levels weremeasured as
per the cell free assay protocol.2.7. Detection of APP695 and APP C-terminal fragments
Primary cortical neurons cultured in 6-well plates (2  106 cells
per well) for 7e10 DIV were treated (as detailed in legends),
washed once with cold PBS, and lysed in SDS-PAGE sample buffer
(62.5 mM Tris, pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol,
and 0.0025% bromophenol blue), centrifuged, and then boiled for
5 minutes. Samples were resolved by 8% Tris-glycine SDS-PAGE for
APP695 and by 16.5% Tris-tricine SDS-PAGE for APP C-terminal
fragments (CTFs) (Hoey et al., 2009). After gel electrophoresis,
proteins were transferred to 0.45 mmnitrocellulose membrane (GE
Healthcare) for APP695 and to 0.2 mm PVDF (Millipore) for APP
CTFs. Immunoblotting for APP695 was performed using primary
antibody for total APP-22C11 (1:2000, Chemicon) and HRP-
conjugated goat anti-rabbit IgG secondary Ab (1:5000, Milli-
pore). Immunoblotting for b tubulin was performed using b
tubulin primary monoclonal b tubulin Ab MAB380 e (1:10,000;
Millipore) and HRP-conjugated goat anti-mouse IgG secondary Ab
(1:5000; dilution Millipore). Immunoblotting for APP CTFs was
performed using primary polyclonal APP Abs CT20 (raised to the
ﬁnal 20 amino acids in the C-terminal of APP695 (1:75,000) and
custom synthesized by Eurogentech, Southampton, UK;
(Perkinton et al., 2004) and HRP-conjugated goat anti-rabbit IgG
secondary Ab (1:200,000; Millipore). Immunoblotting for sAPPa
was performed using 5G11 (rat monoclonal) antibody supernatant
(1:9) courtesy of SFL (Colombo et al., 2012) and HRP-conjugated
goat anti-rat IgG secondary Ab (1:5000, Millipore). APP695,
sAPPa, and b tubulin were detected using the ECL system (GE
Healthcare) and APP CTFs by ECL Advance system (GE Healthcare),
followed by exposure to Hyperﬁlm ECL according to the manu-
facturer’s instructions (GE Healthcare).2.8. ()-Epicatechin feeding study
All animal studies were ethically reviewed and carried out in
accordance with Animals (Scientiﬁc Procedures) Act 1986 and the
GSK Policy on the Care,Welfare, and Treatment of Animals. TASTPM
mice (male), 7 months old, were housed individually in standard
cages. Mice were randomly assigned to groups and drank ()-epi-
catechin supplemented water (3 mg/mL) or vehicle (0.1% ethanol
vol/vol) for 21 days in 5 mL sipper tubes so that liquid intake could
be measured. Intake was estimated to be close to 15 mg ()-epi-
catechin a day, shown previously to equate to nanomolar brain
concentration (Wang et al., 2012). At the end of the experiments,
animals were sacriﬁced and the brains rapidly removed and hem-
isected. One hemisect was immediately immersion ﬁxed in 4%
paraformaldehyde in 0.1 M phosphate buffer saline (PBS, pH 7.4) for
48 hours and used subsequently for immunohistochemistry. The
cortex was dissected from the remaining hemisect and frozen on
dry ice to be used for enzyme-linked immunosorbent assay (ELISA).2.9. Immunohistochemistry
Immunohistochemistry for Ab plaques was performed on 5 mm
sagittal sections. The antibody used was 20G10 (Glaxo Smith Kline,
Harlow, UK; 0.28 mg/mL) (Howlett et al., 2004) raised against the
Ab35e42 fragment and selected for its C-terminal Ab42 speciﬁcity.
Immunohistochemistrywas completedwith appropriate secondary
biotinylated antibodies (Vector Laboratories, Peterborough, UK)
diluted in 1:500 in secondary layer diluent (0.3% Triton-X-100 in
0.1 M PBS), followed by avidin-biotin complexation (Vector ABC,
Vector Laboratories), and visualized using diaminobenzidine ac-
cording to the manufacturer’s data sheets (Vector Laboratories).
The percentage of the total section area labeled by the Ab antibody
in representative sections from eachmouse fed either the control or
()-epicatechin diet was determined using Qwin software macros
(Leica, V2.0) (Howlett et al., 2004).
2.10. Measurement of Ab from TASTPM cultures
TASTPM cortical cultures (7 DIV) were treated with either (Qwin
software)-epicatechin (100 nM), DAPT (10 mM), or vehicle for 6
hours and human Ab1-40 levels in the media measured by ELISA
using a mouse monoclonal capture antibody 1A10 (IBL, Hamburg)
which picks up residues 35-40 of human Ab1-40.
2.11. Measurement of Ab from brain homogenates
A Bio Veris immunoassay was used to measure the levels of
Ab1-40 and Ab1-42 in formic acid extracted cortical homogenates
from ()-epicatechin and vehicle supplemented TASTPM mice.
6E10 antibody (Senetek, Maryland Heights, MO, USA) was used to
capture the entire Ab molecule and Bio Veris tagged G210 or 5G5
were used to detect Ab1-40 and Ab1-42, respectively.
2.12. Quantiﬁcation and statistics
Mean data  standard error of the mean were graphed using
GraphPad Prism 6 software. Immunoblot, Abx-40 ELISA, and Dual-
Glo luciferase activity assay data were analyzed by 1-way analysis
of variance with Bonferroni posttest or by 2-tailed Student t test,
using GraphPad Instat software. Differences between treatments
were deﬁned as statistically signiﬁcant when p < 0.05.
3. Results
3.1. APP-Gal4 driven luciferase gene reporter activity preferentially
reports amyloidogenic processing in primary cortical neurons
A cell based reporter gene assay has been established in primary
cortical neurons, which allows identiﬁcation of g-secretase medi-
ated APP processing modulators (Hoey et al., 2009). This approach
has been used to screen a library of dietary ﬂavonoids. As it has
been proposed that the amyloidogenic and non-amyloidogenic
pathways exist in equilibrium (Colombo et al., 2012; Suh et al.,
2013) and rodent primary neurons appear to favor a BACE1 pro-
cessing route (Hoey et al., 2013), it was ﬁrst necessary to determine
the relative contributions of the a-, b-, and g-secretase enzyme
activities. Treatment with the g-secretase inhibitor DAPT reduced
luciferase expression by approximately 80% (Fig.1A), indicating that
most luciferase expression is driven by g-secretase-mediated APP
cleavage. DAPT did not affect Renilla expression or induce any
morphologic changes in the neurons suggesting that this reduction
in luciferase expression was not because of toxicity. APP undergoes
regulated intramembrane proteolysis; therefore, cleavage by the a-
or b-secretase must occur before g-secretase cleavage. Treatment
Table 1
Flavonoid screen identiﬁed inhibitors of APP-Gal4 dependent-luciferase expression
Flavonoid group Compound name Activity compared
to control in %
100 nM
Fig. 1. APP-Gal4 driven luciferase gene reporter activity preferentially reports amyloidogenic processing in primary cortical neurons. Five DIV primary mouse cortical neurons
chemically transfected with 0.5 mg pRC-APP-Gal4, pFR-luciferase, and pRL-TK-Renilla plasmids using 1 mL/well Lipofectamine-2k. (A) Differential effects of alpha, beta, and gamma
secretase inhibitors on APP-Gal4 gene reporter indicate assay is sensitive to amyloidogenic processing. ** p < 0.01, *** p < 0.001, and **** p < 0.0001 1-way ANOVA with Bonferroni
posttest. (B) Promotion of luciferase signal following cotransfection with 0.5 mg adaptor protein Fe65. **** p < 0.0001 Student t test. (C) Cotransfection with APP-Gal4 plasmid point
mutated at “Swedish” K595N/M596L (APP695 numbering) compared with WT transfection caused increase in processing, sensitive to 10 mM DAPT. **** p < 0.0001 1- way ANOVA
with Bonferroni posttest. Abbreviations: ANOVA, analysis of variance; APP, amyloid precursor protein.
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approximately 50% reduction in luciferase expression (Fig. 1A).
TAPI, a broad-spectrummetalloprotease inhibitor which reduces a-
secretase activity did not reduce but increased luciferase expression
(Fig. 1A) inferring the assay predominantly measured BACE1-
mediated amyloidogenic processing.
To increase the dynamic range of the APP processing-
dependent luminescence, the adapter protein Fe65 was cotrans-
fected and luciferase expression was measured 24 hours later. This
enhanced luciferase expression approximately 10-fold (Fig. 1B)
conﬁrming that the assay was sensitive to physiological stabilizers
of the AICD. The BACE1 sensitivity of the assay predicted that fa-
milial AD mutations known to enhance Ab production, such as the
Swedish mutation of APP (K595 N/M596 L) (Citron et al., 1992)
would increase luciferase expression. Site directed mutagenesis of
the APP-Gal4 vector to incorporate these point mutations resulted
in a 2-fold increase in luciferase expression compared with non-
mutated APP, whereas remaining sensitive to DAPT (Fig. 1C).
Taken together, these data conﬁrmed the assay tractability and the
resultant activity shifts were consistent with the assay being
predominantly a reporter of amyloidogenic APP processing.Flavonol Fisetina 67.7  11.7
Kaempferol 103  54.1
Kaempferol 3O rutinoside 83.0  44.7
Quercetin 98.6  18.1
Flavone Apigenin 90.9  27.9
Apigenin 7O glucoside 102  13.6
Coumarin 137  15.1
Diosmetin 90.4  14.3
Hyperoside 94.1  14.3
Sinensetinb 51.1  26.1*
Flavanone Hesperetin 134  14.5
Narirutin 126  20.7
Anthocyanin Cyanidin chloride 111  39.8
Delphinidin chloride 114  32.9
Pelargonidin chloridea 61.4  6.23
Flavanol (þ) Catechin 97.6  14.7
()-Epicatechin 107  35.1
Epicatechin gallate 115  28.13.2. Flavonoid screen identiﬁed inhibitors of APP-Gal4 dependent
luciferase expression
To date, no comparative systematic study of ﬂavonoid bioac-
tivity at a physiologically relevant concentration has been con-
ducted. To address this, a library of ﬂavonoids were selected and
screened for modulatory effects on the APP-Gal4 driven luciferase
assay. The purpose of the screen was to perform basic structure-
activity analysis to assign favorable inhibitory activity at APP
processing to deﬁned subfamilies of ﬂavonoids. Flavonoids were
tested at 100 nM as a physiologically relevant concentration. Four
ﬂavonoids inhibited APP-Gal4 dependent luciferase expression at
100 nM (Table 1): epigallocatechin (57%), ﬁsetin (67%), pelargo-
nidin chloride (61%), and sinensetin (51%).Epigallocatechinb 57.2  23.3*
Epigallocatechin gallate 91.9  33.6
Five DIV primary cortical neurons were cotransfected with 0.5 mg pRC-APP-Gal4,
pFR-luciferase, and pRL-TK-Renilla, after 0.5 hours; cells were treated with
100 nM ﬂavonoid compound for 24 hours. Cells were lysed and levels of lumines-
cence quantiﬁed using the Dual-Glo luciferase kit according to the manufacturer’s
instructions.
Key: ANOVA, analysis of variance; SD, standard deviation.
a Flavonoids showing largest inhibition of luciferase expression.
b Flavonoids showing largest inhibition of luciferase expression and caused sig-
niﬁcant reduction in luciferase expression (* p ¼ 0.05, 1-way ANOVA with Bonfer-
roni posttest). Values expressed as mean  SD (n ¼ 4).3.3. ()-Epicatechin and epigallocatechin identiﬁed as potent
inhibitors of APP processing
The bioavailability and metabolism of ﬂavanols have been
studied in some depth (Abd El Mohsen et al., 2002; Wang et al.,
2012) and oral administrations of different members of this fam-
ily have reported bioactivity in rodent models (van Praag et al.,
2007) and in humans (Schroeter et al., 2006). Therefore, because
of this established bioavailability, ﬂavanols were the focus of moredetailed concentration and kinetic analyses. Neurons were treated
with ()-epicatechin, epicatechin gallate, epigallocatechin, or epi-
gallocatechin gallate (0.01e10 mM) for 6 and 24 hours. Single ad-
ministrations of ﬂavanols in humans are quickly absorbed and
broken down, with levels back to baseline after 12 hours (Renouf
et al., 2013), therefore a more acute, 6 hour treatment was per-
formed. ()-Epicatechin potently reduced luciferase expression
(EC50 of 20.5 nM) at 6 hours (Fig. 2A) but not 24 hours (data not
shown). In contrast, epigallocatechin potently reduced luciferase
expression (EC50 of 18.6 nM) at 24 hours (Fig. 2B) but not 6 hours
(data not shown). Epicatechin gallate and epigallocatechin gallate
showed no activity at 6 hours or 24 hours (data not shown). The
effects of ()-epicatechin and epigallocatechin were also concen-
tration dependent, showing biphasic activity, no longer inhibiting
APP processing at 10 mM. Epigallocatechin (24 hours) signiﬁcantly
Fig. 2. ()-Epicatechin and epigallocatechin are potent inhibitors of APP processing. (A) ()-Epicatechin is a 3-ringed polyphenol with hydroxyl substitutions at 7 of the A, 3 of C
ring, and 40 , 50 of the B ring. Wild-type primary neuronal cultures were transfected (see Section 2) 0.5 hours later treated with ()-epicatechin for 6 hours. Treatment inhibited bg-
secretase-dependent APP processing with an EC50 of 20.5 nM. (B) Epigallocatechin has the same core structure as ()-epicatechin with additional hydroxyl substitution at position 30
of the B ring. Wild-type primary neuronal cultures were transfected (see Section 2) 0.5 h later treated with epigallocatechin for 24 hours. Epigallocatechin potently inhibited APP
processing with EC50 of 18.6 nM. Abbreviation: APP, amyloid precursor protein.
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secondary cellular target at this higher concentration.
3.4. ()-Epicatechin reduced Ab production in TASTPM primary
neurons
Despite the superior efﬁcacy of epigallocatechin, the fact that
it enhanced APP-cleavage dependent luciferase expression at
10 mM suggested increased amyloidogenic processing at high
concentrations making it unsuitable for consideration as a po-
tential intervention for AD. ()-Epicatechin, although as potent
as epigallocatechin, showed no promotion of luciferase expres-
sion at 10 mM and is blood brain barrier permeable (Abd El
Mohsen et al., 2002; Wang et al., 2012). ()-Epicatechin has
also been shown to have positive effects on memory in in vivo
rodent models (van Praag et al., 2007). For these reasons,
()-epicatechin was taken forward for further investigation.
TASTPM mice express the APP K595 N/M596 L Swedish double
point mutation and the PS1 M146 V familial mutation. They
develop extensive amyloid b pathology as a result of enhanced
amyloidogenic processing from 3 months and exhibit cognitive
deﬁcits evident from 6 months of age (Howlett et al., 2004).
Therefore, an in vitro assessment of ()-epicatechin bioactivity
was undertaken in primary neurons derived from TASTPM em-
bryos. Neurons were treated with ()-epicatechin (100 nM for 6
hours), and the levels of Ab released into the media were
assessed by ELISA. The g-secretase inhibitor DAPT led to a 3-fold
reduction in Ab1-40 levels indicating that the Ab detected in the
media resulted from g-secretase mediated APP cleavage events
and not from cytotoxicity or nonspeciﬁc proteolysis (Fig. 3A).
()-Epicatechin decreased Ab1-40 levels by approximately 30%,
consistent with inhibition of bg processing of APP as suggested by
the initial in vitro work (Fig. 3A). Ab1-42 levels were below the
detection limit of the assay (data not shown).
3.5. Oral ()-epicatechin delivery reduces Ab pathology in TASTPM
mice
To explore the potential of ()-epicatechin as an effective
protective molecule against AD-like pathology, 7-month-old
TASTPM mice were given 15 mg/d ()-epicatechin in drinking
water for 21 days. Animals were then sacriﬁced and cortical
Abx-40,42 plaque load and soluble Ab levels were assessed. Ab
plaque load was reduced by approximately one-third (Fig. 3B and
C), whereas levels of soluble Ab1-40 and Ab1-42 both showeddownward trends (Fig. 3D and E). These observations show, for
the ﬁrst time, that short term administration of orally delivered
()-epicatechin reduced Ab pathology in the cortex of an aged
transgenic model of AD.
For the development of ()-epicatechin as an AD treatment or to
be able tomake dietary recommendations it is important to address
the mechanism of action. Flavanols have been shown previously to
reduce Ab pathology (Rezai-Zadeh et al., 2008; Wang et al., 2008),
however the mechanism remains controversial.
3.6. ()-Epicatechin treatment does not affect APP695, sAPPa, or a-
CTF levels but reduces b-CTF formation
Although these results were consistent with an inhibition of
bg-processing there were a number of potential mechanisms
which could explain this phenomenon as reduction in Ab levels
could result from: inhibition of BACE1 or g-secretase activity,
increased a-secretase activity, or following changes in APP
expression. To investigate if the inhibitory actions of ()-epi-
catechin were the result of changes in APP expression, primary
neurons were treated with 100 nM ()-epicatechin over 24
hours, and APP695 levels in total cell lysates were measured by
Western blot analysis using either a C-terminal (Fig. 4A) or an N-
terminal (Fig. 4B) directed APP antibody. No signiﬁcant change in
total APP levels were observed (Fig. 4A and B), indicating that
()-epicatechin was not acting to downregulate APP levels either
through inhibition of translation or increased protein turnover.
Previous studies investigating the effects of structurally similar
ﬂavanols on APP processing have suggested modulation of a-
secretase as the likely mechanism of action (Fernandez et al.,
2010; Obregon et al., 2006). To investigate this possibility, 6 DIV
primary neuronal cultures were treated with ()-epicatechin (0.1
or 10 mM) or a known stimulator of a-secretase, NMDA, for
20 minutes, 6 hours and 24 hours, and the production of APP
CTFs was measured. NMDA (50 mM) caused a time-dependent
increase in the levels of a-CTF (Fig. 4A) consistent with
enhancement of a-secretase processing as previously reported
(Hoey et al., 2009). In contrast, ()-epicatechin showed no time
or concentration-dependent changes in a-CTF levels suggesting
that a-secretase was unlikely to be the primary target (Fig. 4A).
This was further supported by analysis of sAPPa secretion which
was not altered following treatment with ()-epicatechin. As a-
secretase was not affected by ()-epicatechin treatment the ef-
fect on b-CTF formation was examined more closely. As before,
neuronal cultures were treated with ()-epicatechin (0.1 or
Fig. 3. ()-Epicatechin reduces Ab levels in TASTPM transgenic mouse model. (A) Seven
DIV TASTPM primary cortical neurons were treated for 6 hours with either vehicle,
100 nM ()-epicatechin or 10 mM DAPT. Ab1-40 levels were assessed by ELISA using
monoclonal 1A10. *** p < 0.001 and **** p < 0.0001 1-way ANOVA with Bonferroni
posttest, n ¼ 6. (B) A 21-day oral delivery of ()-epicatechin (15 mg/d in drinking water)
reduced Ab plaque load in TASTPM transgenic mouse. Representative 5 mm sagittal
section taken after completion of feeding study. Mouse monoclonal Abx-42 speciﬁc 20G10
used to stain (i) control and (ii) ()-epicatechin (15 mg/d) treated TASTPM mice.
Scale bar ¼ 200 mM. (C) Quantiﬁed as percentage area labeled with Abx-42 antibody.
* p < 0.05 Student t test n ¼ 5. (D and E) Trend toward decreasing levels of soluble Ab1-42
and Ab1-40 levels following ()-epicatechin diet, n ¼ 4. Abbreviations: Ab, amyloid beta;
ANOVA, analysis of variance; ELISA, enzyme-linked immunosorbent assay.
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and the production of APP CTFs was measured. ()-Epicatechin
treatment resulted in a clear trend toward reduced levels of b-
CTF fragments likely representing lower levels of C99 (b-CTF), p-
b0-CTF (C89) and/or b0-CTF (Fig. 4C), and consistent with reduced
b-secretase processing.3.7. ()-Epicatechin modulates BACE1 enzyme activity indirectly
Alterations in APP processing could quite possibly result
from changes in the expression of the secretases involved. Toinvestigate, these neuronal cultures were treated with ()-epi-
catechin (100 nM) for 0.5e6 hours, and levels of the primary a-
secretase ADAM10 and BACE1 were measured by immunoblotting.
The levels of ADAM10 and BACE1 were not altered by ()-epi-
catechin treatment (Fig. 5A), suggesting that the acute inhibitory
effects on APP processing were not because of changes in secretase
expression. An alternative hypothesis was that ()-epicatechin
was acting to inhibit to g-secretase activity. To investigate
whether ()-epicatechin was acting through g-secretase, a Notch-
Gal4 luciferase reporter assay was used. Primary neuronal cultures
were treated with ()-epicatechin (0.1e10 mM) or DAPT (10 mM)
for 6 hours and luciferase expression measured. DAPT caused a
substantial reduction (approximately 90%) in luciferase expression
demonstrating that the assay was sensitive to g-secretase cleavage
of Notch. ()-Epicatechin did not affect luciferase expression at
either concentration tested (Fig. 5B), indicating its bioactivity was
not at the level of g-secretase. As a- and g-secretases did not
appear to mediate the inhibitory actions of ()-epicatechin, and
there were no changes in secretase expression; activity at BACE1
was considered the most likely target. To address this, a cell free
recombinant BACE1 assay was used. ()-Epicatechin (0.01e10 mM)
had no direct effect on BACE1 activity in this assay suggesting it
was not acting as a direct catalytic inhibitor (data not shown).
Alternatively, noncatalytic actions might be responsible for the
inhibitory effects of ()-epicatechin. Cultured neurons were
therefore, treated with ()-epicatechin (0.01e10 mM) for 6 hours,
lysates prepared and incubated with a synthetic BACE1 substrate
to measure endogenous BACE1 activity. Under these conditions
()-epicatechin (100 nM) reduced BACE1 activity by 72%
compared with the BACE inhibitor bsI (Fig. 5C). In comparison,
epigallocatechin caused maximum inhibition (86%) at 1 mM. At
higher concentrations of ()-epicatechin and epigallocatechin
there was no inhibition of BACE1 activity.
4. Discussion
The current failure rate of AD drugs has driven research interests
toward alternative small molecules with therapeutic potential for
reducing risk or slowing progression of dementia. Mounting evi-
dence suggests that selected dietary ﬂavonoids, polyphenolic
compounds with steroid-like structures, are able to reduce Ab pa-
thology and show positive effects on learning and memory
(Williams and Spencer, 2012). There is however, a lack of consensus
on the precise identities of the bioactive molecules and mecha-
nisms underlying these potentially beneﬁcial effects as the con-
centrations used inmany studies far exceed those achievable in vivo
and ﬂavonoids generally have very poor bioavailability.
In this study, an in vitro screen of dietary ﬂavonoids in primary
neurons led to the identiﬁcation of ()-epicatechin and epi-
gallocatechin as potent (nanomolar) inhibitors of amyloidogenic
APP processing. Studies in aged TASTPM transgenic mice showed
that oral administration of ()-epicatechin reduced Ab pathology.
This reduction was seen following 21 days of ()-epicatechin
treatment, the ﬁrst time oral administration has been shown to be
effective on such a short timescale. Mechanistic studies revealed
the likely mode of action of ()-epicatechin was through indirect,
noncatalytic BACE1 inhibition and not throughmodulation of either
a-secretase or g-secretase activity.
The initial unbiased in vitro ﬂavonoid screen was conducted
using an APP-Gal4-driven luciferase gene reporter assay which
has been shown to preferentially report amyloidogenic process-
ing when used in primary cultured neurons (Hoey et al., 2009,
2013). This was conﬁrmed in this study as luciferase gene re-
porter expression was inhibited by commercial b- and g- secre-
tase inhibitors, enhanced by Fe65 cotransfection and increased
Fig. 4. ()-Epicatechin causes a trend toward reduced b-CTF without affecting APP levels
or a-secretase mediated APP metabolites. (A) ()-Epicatechin does not cause a time or
concentration dependent alteration in total APP levels or a-CTF levels as seenwith 50 mM
NMDA (a) 20 minutes, (b) 6 hours, and (c) 24 hours treatment. Western blot was per-
formed with monoclonal CT20 (1:75,000) antibody. (B) No signiﬁcant change in sAPPa or
total APP695 protein levels following 0.1 mM ()-epicatechin over time course from 0.5 to
24 hours. Western blot analysis was performed with monoclonal antibody supernatant
5G11 for sAPPa (1:9), antibody 22C11 for APP (1:5000), and T8328 b tubulin (1:10,000),
representative blots are shown. (C) ()-Epicatechin (0.1 mM) caused a trend toward a
time-dependent reduction in b-CTF levels in the absence of increased a-CTF levels
measured at (a) 20 minutes, (b) 6 hours, and (c) 24 hours treatment, n ¼ 3. Abbreviation:
APP, amyloid precursor protein; CTF, C-terminal fragments.
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Ab formation. Inhibition of a-secretase activity tends to enhance
luciferase expression. This assay is therefore, a powerfultechnique for screening compounds with potential bioactivity at
different points in the pathways regulating APP processing and is
not simply a tool for identifying direct catalytic inhibitors of b-
and g- secretase. Using this approach, 4 ﬂavonoids were identi-
ﬁed that reduced APP cleavage-dependent luciferase expression
at 100 nM (24 hours): ﬁsetin, pelargonidin, sinensetin, and epi-
gallocatechin. Fisetin has previously been identiﬁed as an acti-
vator of signaling pathways implicated in learning and memory
(Maher et al., 2006). Pelargonidin as the major constituent of
strawberries has been implicated in reversing age-related
cognitive decline (Joseph et al., 1999). Sinensetin has been
much less studied but very recently was shown to activate cyclic
AMP response element-mediated transcription in rat hippocam-
pal neurons, a key pathway in neuroprotection (Kawahata et al.,
2013) and to have anti-angiogenic effects in a zebraﬁsh model
(Lam et al., 2012). Whether these activities of ﬁsetin, pelargoni-
din, and sinensetin are related to or additional to, the inhibitory
actions at APP processing is unknown. Epigallocatechin was
perhaps the most signiﬁcant positive hit from the assay, as it is a
member of an intensively studied family of ﬂavanol molecules
called the catechins which have known bioavailability in a variety
of mammalian models (Ho et al., 2013; van Praag et al., 2007) and
have been previously postulated to have therapeutic potential for
neurodegeneration (Mandel et al., 2011; Pasinetti, 2012).
Further kinetic analysis of the catechin family revealed that
()-epicatechin, in addition to epigallocatechin, possessed potent
inhibitory actions but only when applied for shorter time points,
and this inhibition was not apparent at longer time points
potentially because of metabolism into an inactive form or dif-
ferences in membrane permeability. Indeed, ()-epicatechin was
effective at 6 hours although epigallocatechin required 24 hours
to reduce APP processing. This difference in biokinetics between
()-epicatechin and epigallocatechin might be because of faster
metabolism for ()-epicatechin together with lesser membrane
permeability for epigallocatechin. Concentration analyses
revealed that ()-epicatechin and epigallocatechin showed
biphasic effects, losing their inhibitory properties and in the case
of epigallocatechin, stimulating APP processing at higher micro-
molar concentrations. This biphasic proﬁle has been reported
previously for ﬂavonoid modulation of the ERK and Akt signaling
pathways in neurons (Vauzour et al., 2007) and suggests that
concentration is a critical determinant of ﬂavonoid selectivity.
()-Epicatechin and other monomeric proanthocyanidins have
been shown to reach concentrations of 200e400 nM in rodent
brain following oral dosage (Abd El Mohsen et al., 2002;Wang et al.,
2012) and to promote pathways associated with learning and
memory (Haque et al., 2008; van Praag et al., 2007; Wang et al.,
2012) supporting the basic notion that oral administration of
()-epicatechin might impact on AD pathology. Indeed, oral
administration of ()-epicatechin (approximately 15 mg/d) via
drinking water for 21 days reduced Ab pathology in TASTPMmice at
an age when plaque burden was already well established (Howlett
et al., 2004). This may go part way to explain the relatively modest
reductions in pathology compared with other in vivo ﬂavonoid
studies such as those testing phenolic compounds, grape poly-
phenols and EGCG in Tg2576 mice, where administration was
initiated at 5, 7, and 8months respectively when plaque burdenwas
not established until 9 months (Hamaguchi et al., 2009; Hsiao et al.,
1996; Rezai-Zadeh et al., 2008; Wang et al., 2012). The reductions
reported here are important however, as previously; only intra-
peritoneal injected ﬂavonoid has been shown to have such short-
term effects with a-7 day treatment of curcumin reducing plaques
and Ab levels (Garcia-Alloza et al., 2007). The precise mechanism
underlying this favorable reduction in Ab pathology is as yet un-
clear and serious consideration needs to be given as to whether
Fig. 5. ()-Epicatechin indirectly modulates BACE1 activity independent of BACE1 or ADAM10 expression changes and without affecting notch activity. (A) Epicatechin treatment
does not affect a- or b-secretase levels in primary cortical neurons as seen following vehicle (C) or ()-epicatechin (0.1 mM) for 30 minutes or 6 hours. Western blot analysis was
performed for ADAM10 (735e749) (1:2000), BACE1 (2C13) (1:2000), or b tubulin (1:10,000). (i) Representative blots, (ii) ADAM10 quantiﬁcation, and (iii) BACE1 quantiﬁcation. N ¼
4 from 2 independent experiments. (B) ()-Epicatechin does not affect g-secretase activity: 5 DIV WT primary neuronal cultures were transfected with 0.5 mg Notch-Gal4, pFR-
luciferase, and pRL-TK-Renilla and treated with ()-epicatechin or 10 mM DAPT 0.5 hours later for 6 hours. **** p < 0.0001 1-way ANOVA with Bonferroni posttest. (C) Reduction of
BACE1 activity in primary cell lysates treated with ()-epicatechin and epigallocatechin. Primary neuronal cultures were treated with ()-epicatechin (6 hours) or epigallocatechin
(24 hours), the cells were then lysed and levels of BACE1 activity was measured using a synthetic peptide substrate. Data are represented as percentage inhibition compared with
bsI. Abbreviations: ANOVA, analysis of variance; bsI, b-secretase inhibitor; WT, wild type.
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reduction in Ab pathology following only 21 days of administration.
Flavanols have been proposed to have multimodal activities
(Mandel et al., 2008), concurrently acting at multiple targets and
could potentially impact on Ab aggregation by favoring the for-
mation of off-target oligomers (Ehrnhoefer et al., 2008) but only if
micromolar concentrations could be achieved in vivo. This is not a
mechanism that has been addressed here as the focus was on APP
processing, but the ability of ()-epicatechin to disrupt oligomeric
Ab formation should be tested under these conditions. Further
studies should assess the effects of ()-epicatechin on Ab oligomer
formation and clearance. Epigallocatechin-3-gallate (EGCG) has
also been reported to increase a-secretase activity through
increased maturation of ADAM10 (Fernandez et al., 2010; Rezai-
Zadeh, 2005), but this does not appear to be the primary mecha-
nism involved here as there was no evidence of a change in the
levels of a-CTFs, sAPPa, or ADAM10 following ()-epicatechin
treatment. This difference could be because of cell type speciﬁcity,
different modes of action because of lack of the gallic acid moiety in
()-epicatechin or simply because of differences in the concentra-
tions used, and it is quite possible that actions at a-secretase will be
observed under different dosing regimes. The most direct potential
mechanism for the observed ()-epicatechin effect would be in-
hibition of BACE1, and a number of studies have suggested this as a
potential mode of action for ﬂavonoids. In silico docking studiessuggested a number of ﬂavonoids might act as direct catalytic in-
hibitors of BACE1 (Shimmyo et al., 2008). ()-Epicatechin and
epigallocatechin did not inhibit BACE1 activity in a recombinant
enzyme assay, suggesting this mechanism of action is unlikely.
Treatment with ()-epicatechin and epigallocatechin did, however,
reduce endogenous BACE1 activity suggesting an indirect inhibitory
mechanism of action. How this is achieved is unclear but could
involve actions at an allosteric site, posttranslational modiﬁcation,
downregulation of BACE1 expression, or modulation of BACE1
localization as recently reported with the plant-derived phytosterol
stigmasterol (Burg et al., 2013). With respect to the development of
()-epicatechin for use in humans an important consideration was
the potential for inhibitory actions at g-secretase as there have been
a number of recent clinical trial failures for AD drugs because of off
target effects at notch, leading to gastrointestinal and immune cell
toxicity (Doody et al., 2013; Imbimbo et al., 2011). ()-Epicatechin
did not inhibit notch cleavage at any concentration tested, sug-
gesting that this is unlikely to be a signiﬁcant hurdle to the devel-
opment of ()-epicatechin as a potential treatment or prophylactic
for AD. Before that can happen the bioavailability and pharmaco-
kinetics of ()-epicatechin and its principle in vivo metabolites will
need to be thoroughly addressed, and the loss of favorable ﬂavanol
activity at high concentrations could be an issue.
In conclusion, this study has identiﬁed a single ﬂavanol,
()-epicatechin, to be effective at reducing Ab production and
C.J. Cox et al. / Neurobiology of Aging 36 (2015) 178e187186pathology in wild-type neurons and in a transgenic model of AD
and that this is most likely through modulation of BACE1 activity.
Given that Ab toxicity is almost certainly initiated at presymp-
tomatic stages of AD, any potential beneﬁt from an ()-epicatechin
intervention would be most likely achieved through a risk reduc-
tion strategy rather than as a treatment. The challenge now is to
move beyond the epidemiology which has hinted at positive effects
of ﬂavonoid rich diets on the development of dementia (Dai et al.,
2006; Kuriyama et al., 2006; Letenneur et al., 2007), into clinical
trials to directly test efﬁcacy in at risk individuals or thosewithmild
cognitive impairment.
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